Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathochemistry, pathogenesis and enzyme replacement in multiple-sulfatase deficiency.

Y Eto1, I Gomibuchi, F Umezawa

  • 1Department of Pediatrics, Tokyo Jikei University School of Medicine, Japan.

Enzyme
|January 1, 1987
PubMed
Summary

Multiple-sulfatase deficiency (MSD) is a heterogeneous disorder. In neonatal MSD, decreased arylsulfatase A activity stems from accelerated enzyme degradation, distinct from other forms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Training in evaluation of expressed emotion using the Japanese version of the Camberwell Family Interview.

Acta psychiatrica Scandinavica·1995
Same author

Hypoglycemia associated with localized fibrous mesothelioma of the pleura.

Journal of UOEH·1995
Same author

Growth of human gastric carcinomas and expression of epidermal growth factor, transforming growth factor-alpha, epidermal growth factor receptor and p185c-erbB-2.

Oncology·1995
Same author

Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene.

Nature·1995
Same author

Small peripheral lung carcinoma evaluated with incremental dynamic CT: radiologic-pathologic correlation.

Radiology·1995
Same author

The Ras suppressor RSU-1 localizes to 10p13 and its expression in the U251 glioblastoma cell line correlates with a decrease in growth rate and tumorigenic potential.

Oncogene·1995

Area of Science:

  • Biochemistry
  • Genetics
  • Metabolic Disorders

Background:

  • Multiple-sulfatase deficiency (MSD) presents with heterogeneous clinical phenotypes.
  • Neonatal MSD exhibits severe symptoms and minimal arylsulfatase A, B, and C activity in fibroblasts.
  • Neonatal MSD is distinguished from late infantile-type MSD by lack of thiosulfate enhancement of arylsulfatase A activity.

Purpose of the Study:

  • To investigate the underlying mechanisms of arylsulfatase A deficiency in neonatal MSD.
  • To explore potential therapeutic strategies for MSD using enzyme replacement and cell-based therapies.

Main Methods:

  • Cultured skin fibroblasts from MSD patients were used.
  • Enzyme activities (arylsulfatase A, B, C) and 14C-sulfatide degradation were measured.

Related Experiment Videos

  • Enzyme replacement therapy with human and fungal arylsulfatases was performed.
  • Leukocyte co-culture was utilized to assess therapeutic potential.

    • Main Results:

    • Degradation of 14C-sulfatide was significantly higher in MSD fibroblasts compared to late infantile-type MLD.
    • Leupeptin treatment enhanced arylsulfatase A activity and 14C-sulfatide degradation in MSD fibroblasts, suggesting accelerated enzyme degradation.
    • Human-derived arylsulfatases A and B were effectively taken up by MSD cells.
    • Co-culture with leukocytes corrected arylsulfatase A and B activities in MSD fibroblasts.

    Conclusions:

    • Accelerated degradation of arylsulfatase A is a key factor in neonatal MSD.
    • Enzyme replacement with human arylsulfatases and leukocyte-based therapy show promise for treating MSD.